Accounts filed by Janssen Sciences Ireland UC show that revenues also dipped, by 2pc to €11.39bn.
The firm paid a dividend of €5.9bn to its parent, Janssen R&D Ireland Unlimited Company.
Pre-tax profits of €6.9bn had been recorded in 2023 when they benefited from a €3.2bn dividend from a subsidiary.
The Ringaskiddy-registered company recorded post-tax profits of €3.93bn in 2024 after incurring a corporation tax charge of €544.13m. This followed a corporation tax charge of €616m in 2023.
On risks to the business, the directors state that the global geopolitical landscape continues to be unpredictable, with ongoing tensions that have the potential to disrupt markets and supply chains. These could introduce new cost pressures, particularly on raw materials, putting additional strain on business costs.
In a post-balance sheet event, the directors disclose that on June 23 this year the company proposed to make a distribution of €5.2bn to the company’s sole shareholder, GH Biotech Holdings Limited.
The firm recorded an operating profit last year of €4.7bn and €206.3m in other finance expenses, while €40.47m in net interest payments reduced the firm’s profits to a pre-tax profit of €4.47bn.
Numbers employed by the business last year increased from 1,188 to 1,309 and staff costs rose from €132.45m to €162.34m. Pay to directors totalled €2.49m, which included €396,000 for compensation for loss of office.
The principal activity of the company is the research, development, manufacture and commercialisation of pharmaceutical products for the treatment of various diseases. It also manufactures biomedical products.
A breakdown of the firm’s revenues show that €539m in sales were recorded in the Republic of Ireland, €5.4bn in North America and €5.45bn in the EMEA.
The profit last year takes account of €913m in non-cash amortisation costs and €1bn in R&D.
The company had shareholder funds of €34bn on December 29 that included accumulated profits of €6.1bn.
The directors state that in another post balance sheet event on June 23, a subsidiary Janssen Irish Finance Unlimited Company proposed to make a €4.3bn distribution to the company.
source